$VRPX
Virpax Pharmaceuticals, Inc.

2023 Q4 Form 10-Q Financial Statement

#000121390023093897 Filed on December 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.589M $4.620M $4.910M
YoY Change 105.72% -5.92% 216.46%
% of Gross Profit
Research & Development $1.096M $1.496M $2.805M
YoY Change -19.3% -46.68% 601.28%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.684M $6.115M $7.715M
YoY Change 51.0% -20.74% 1828.79%
Operating Profit -$6.115M -$7.715M
YoY Change -20.74% 137.41%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $122.4K $120.6K $73.25K
YoY Change 6.45% 64.7% 16.42%
Pretax Income -$4.562M -$5.994M -$7.642M
YoY Change 52.71% -21.56% 137.64%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.562M -$5.994M -$7.642M
YoY Change 52.71% -21.56% 137.64%
Net Earnings / Revenue
Basic Earnings Per Share -$0.51 -$0.65
Diluted Earnings Per Share -$3.90 -$0.51 -$0.65
COMMON SHARES
Basic Shares Outstanding 11.71M shares 11.71M shares 11.71M shares
Diluted Shares Outstanding 11.71M shares 11.71M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.142M $12.15M $20.56M
YoY Change -51.87% -40.9% -50.71%
Cash & Equivalents $9.142M $12.15M $20.56M
Short-Term Investments
Other Short-Term Assets $486.8K $885.4K $3.073M
YoY Change -28.23% -71.19% 97.05%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.628M $13.04M $23.64M
YoY Change -51.06% -44.84% -45.38%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $9.628M $13.04M $23.64M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $9.628M $13.04M $23.64M
YoY Change -51.06% -44.84% -45.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.000M
YoY Change
Accrued Expenses $493.8K $595.6K $311.2K
YoY Change -24.59% 91.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.694M $6.533M $4.208M
YoY Change 148.63% 55.25% 132.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $7.694M $6.533M $4.208M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $7.694M $6.533M $4.208M
YoY Change 148.63% 55.25% 132.25%
SHAREHOLDERS EQUITY
Retained Earnings -$59.54M -$54.98M -$41.37M
YoY Change 34.25% 32.91%
Common Stock $12.00 $117.00 $117.00
YoY Change -89.74% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.934M $6.506M $19.43M
YoY Change
Total Liabilities & Shareholders Equity $9.628M $13.04M $23.64M
YoY Change -51.06% -44.84% -45.38%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$4.562M -$5.994M -$7.642M
YoY Change 52.71% -21.56% 137.64%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.011M -$2.652M -$5.499M
YoY Change 92.14% -51.76% 15.94%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.011M -2.652M -5.499M
Cash From Investing Activities
Cash From Financing Activities 0.000
Net Change In Cash -3.011M -2.652M -5.499M
YoY Change 92.14% -51.76% -117.6%
FREE CASH FLOW
Cash From Operating Activities -$3.011M -$2.652M -$5.499M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.59
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11714284 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11714284 shares
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40064
dei Entity Registrant Name
EntityRegistrantName
VIRPAX PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1510982
dei Entity Address Address Line1
EntityAddressAddressLine1
1055 Westlakes Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Berwyn
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19312
dei City Area Code
CityAreaCode
(610)
dei Local Phone Number
LocalPhoneNumber
727-4597
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 Par Value Per Share
dei Trading Symbol
TradingSymbol
VRPX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11714284 shares
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12152993 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18995284 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
885394 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
678365 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
13038387 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
19673649 usd
CY2023Q3 us-gaap Assets
Assets
13038387 usd
CY2022Q4 us-gaap Assets
Assets
19673649 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1532723 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1094590 usd
CY2023Q3 us-gaap Litigation Reserve Current
LitigationReserveCurrent
5000000 usd
CY2022Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
2000000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6532723 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3094590 usd
CY2023Q3 us-gaap Liabilities
Liabilities
6532723 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3094590 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11714284 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11714284 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11714284 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11714284 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
117 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
117 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61487973 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
60933569 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54982426 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44354627 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6505664 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16579059 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13038387 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19673649 usd
CY2023Q3 vrpx Net Of Insurance Reimbursement
NetOfInsuranceReimbursement
0 usd
vrpx Net Of Insurance Reimbursement
NetOfInsuranceReimbursement
1250000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4619519 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4910039 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6983670 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9338070 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1495619 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2805103 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4022020 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9404980 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
6115138 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7715142 usd
us-gaap Operating Expenses
OperatingExpenses
11005690 usd
us-gaap Operating Expenses
OperatingExpenses
18743050 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6115138 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7715142 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11005690 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18743050 usd
CY2023Q3 us-gaap Other Income
OtherIncome
120640 usd
CY2022Q3 us-gaap Other Income
OtherIncome
73252 usd
us-gaap Other Income
OtherIncome
377891 usd
us-gaap Other Income
OtherIncome
79443 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5994498 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7641890 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10627799 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18663607 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5994498 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7641890 usd
us-gaap Net Income Loss
NetIncomeLoss
-10627799 usd
us-gaap Net Income Loss
NetIncomeLoss
-18663607 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.59
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11714284 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11713379 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11714284 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11711624 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37484745 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
211340 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5137002 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
32559083 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
244701 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5884715 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
26919069 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
150717 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7641890 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
19427896 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16579059 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
140583 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1520534 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15199108 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
218257 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3112767 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
12304598 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
195564 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5994498 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6505664 usd
us-gaap Net Income Loss
NetIncomeLoss
-10627799 usd
us-gaap Net Income Loss
NetIncomeLoss
-18663607 usd
us-gaap Share Based Compensation
ShareBasedCompensation
554404 usd
us-gaap Share Based Compensation
ShareBasedCompensation
606758 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
207029 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
342706 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
438133 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2120174 usd
vrpx Increase Decreasein Estimated Litigation Liability
IncreaseDecreaseinEstimatedLitigationLiability
3000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6842291 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16279381 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6842291 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-16279381 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18995284 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36841992 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12152993 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20562611 usd
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-05-12
us-gaap Net Income Loss
NetIncomeLoss
-10627799 usd
us-gaap Net Income Loss
NetIncomeLoss
-18663607 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54982426 usd
CY2023Q3 vrpx Estimated Litigation Liability
EstimatedLitigationLiability
5000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b> — The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant items subject to such estimates and assumptions include research and development accruals and prepaid expenses, estimated litigation liability, and the valuation of stock-based compensation. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p>
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
156754 usd
CY2023Q3 vrpx Prepaid Research And Development
PrepaidResearchAndDevelopment
448429 usd
CY2023Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
11900000 usd
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
18700000 usd
us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.50 pure
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
406853 usd
CY2022Q4 vrpx Prepaid Research And Development
PrepaidResearchAndDevelopment
496270 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
30112 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
25341 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
885394 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
678365 usd
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
537054 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
654765 usd
CY2023Q3 vrpx Accrued Severance
AccruedSeverance
58500 usd
CY2023Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
210622 usd
CY2023Q3 vrpx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
422176 usd
CY2022Q4 vrpx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
254904 usd
us-gaap Legal Fees
LegalFees
178889 usd
us-gaap Legal Fees
LegalFees
147277 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
92290 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
33192 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
37644 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1532723 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1094590 usd
CY2023Q1 vrpx Net Of Insurance Reimbursement
NetOfInsuranceReimbursement
1250000 usd
CY2023Q4 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
14684833 usd
CY2023Q4 vrpx Net Sales Of Epoladerm
NetSalesOfEpoladerm
0.05 pure
CY2023Q4 vrpx Net Sales Of Envelta
NetSalesOfEnvelta
0.075 pure
CY2023Q4 vrpx Loss Contingency Exemplary Damage Value
LossContingencyExemplaryDamageValue
13400000 usd
us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
6.7 usd
CY2023Q3 vrpx Proffered Documents
ProfferedDocuments
1182 shares
us-gaap Payments For Fees
PaymentsForFees
28382 usd
CY2022 us-gaap Litigation Settlement Interest
LitigationSettlementInterest
2000000 usd
us-gaap Litigation Settlement Interest
LitigationSettlementInterest
5000000 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
3000000 usd
CY2023Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
2000000 usd
CY2022Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
146029 usd
vrpx Christopher Chipman Separation Agreement Description
ChristopherChipmanSeparationAgreementDescription
(i) severance in the amount of $234,000, payable in four equal installments of $58,500, subject to all withholdings, on the Company’s first payrolls dates following July 1, 2023, August 1, 2023, September 1, 2023, and October 1, 2023, respectively; (ii) COBRA reimbursement in the amount of $13,385 which represents four months of COBRA payments; and (iii) accelerated vesting of 238,126 shares subject to Mr. Chipman’s outstanding stock options. Mr. Chipman’s separation from the Company was effective June 30, 2023.
CY2023Q3 us-gaap Loss Contingency Accrual Product Liability Gross
LossContingencyAccrualProductLiabilityGross
58500 usd
CY2023Q3 us-gaap Loss Contingency Accrual Product Liability Gross
LossContingencyAccrualProductLiabilityGross
58500 usd
CY2023Q3 us-gaap Loss Contingency Accrual Product Liability Gross
LossContingencyAccrualProductLiabilityGross
58500 usd
CY2023Q4 us-gaap Loss Contingency Accrual Product Liability Gross
LossContingencyAccrualProductLiabilityGross
58500 usd
CY2023Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
58500 usd
CY2022Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
0 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11714284 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11714284 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11714284 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11714284 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
18436 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.89
us-gaap Stock Option Exercise Price Decrease
StockOptionExercisePriceDecrease
12.5
CY2022Q2 vrpx Reserving Shares
ReservingShares
1500000 shares
CY2022Q2 vrpx Annual Increase
AnnualIncrease
0.02 pure
us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
The 2022 Plan reserves an aggregate of (i) 1,500,000 shares of the Company’s common stock for the issuance of awards under the 2022 Plan (all of which may be granted as an Incentive Stock Option, or ISOs) plus (ii) an additional number of shares of common stock subject to outstanding awards under the 2017 Plan that become forfeited or canceled without payment or which are surrendered in payment of the exercise price and/or withholding taxes (collectively, the “Share Limit”). Pursuant to the 2022 Plan’s “evergreen” provision, the Share Limit shall be cumulatively increased on January 1, 2023, and on each January 1 thereafter, by 2% of the number of shares of common stock issued and outstanding on the immediately preceding December 31 or such lesser number of shares as determined by the Board. The 2022 Plan increased by 234,286 shares on January 1, 2023.
vrpx Unvested Restricted Stock Awards
UnvestedRestrictedStockAwards
0 shares
CY2022 vrpx Unvested Restricted Stock Awards
UnvestedRestrictedStockAwards
237 shares
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
0 shares
us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
451 shares
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
0 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
4688 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
2342 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
32831 usd
CY2023Q3 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
195564 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
552060 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
573927 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
195564 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
150717 usd
us-gaap Share Based Compensation
ShareBasedCompensation
554404 usd
us-gaap Share Based Compensation
ShareBasedCompensation
606758 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y5M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0367 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0196 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1312 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7712 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q3 vrpx Options Outstanding Shares
OptionsOutstandingShares
1172281 shares
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
209980 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1008500000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.78
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1008500000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.78
vrpx Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M9D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
46432 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
212000000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y6M29D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8344 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease
100000 shares
CY2023Q2 vrpx Exercise Price Per Share
ExercisePricePerShare
0.99
us-gaap Defined Benefit Plan Pension Method To Determine Vested Benefit Obligation
DefinedBenefitPlanPensionMethodToDetermineVestedBenefitObligation
The options granted to the Chief Financial Officer vest as follows: (i) 25% shall vest upon the one-year anniversary from his hire date and (ii) the remaining 75% shall vest in thirty-six equal monthly installments. On August 15, 2023, the remaining 75% vesting term was amended from thirty-six months to twenty-four months. The options have a ten-year expiration date.
CY2023Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
238126 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.63
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P1Y6M29D
vrpx Description Of Lipocure Agreement
DescriptionOfLipocureAgreement
Under the Lipocure Agreement, the Company was required to pay an upfront fee upon signing of $150,000 and is required to make future milestone and royalty payments to Lipocure. The Company is obligated to make aggregate milestone payments of up to $19.8 million upon the achievement of specified development and commercial milestones. Lipocure met the development milestone of $300,000 in the third quarter of 2023 for successfully completing a formulation for the Licensed Product. The Company paid $150,000 in the third quarter of 2023 and will pay the balance in the fourth quarter of 2023. Royalty payments must be paid in an amount equal to a single digit to low double-digit percentage of annual net sales of royalty qualifying products, subject to certain adjustments. Royalties shall be payable during the period of time, on a country-by-country basis, commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on July 24, 2030.
CY2021Q2 vrpx Service Fees
ServiceFees
337500 usd
vrpx Description Of Agreement Rendering Of Research Services
DescriptionOfAgreementRenderingOfResearchServices
In consideration for the research services, the Company agreed to pay research service fees of $1,286,000 in four equal quarterly installments ($321,500 per calendar quarter), as well as reasonable pass-through expenses. All services to be provided under the January 2023 Lipocure Research Agreement initiated on January 1, 2023, and are anticipated to be completed towards the end 2023.
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
usd
vrpx Increase Decreasein Estimated Litigation Liability
IncreaseDecreaseinEstimatedLitigationLiability
usd
CY2022Q4 vrpx Accrued Severance
AccruedSeverance
usd
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
usd
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
vrpx Share Based Compensation Arrangement By Share Based Payment Award Options Exercise Price Cancelled Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceCancelledWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001708331

Files In Submission

Name View Source Status
vrpx-20230930_lab.xml Edgar Link unprocessable
0001213900-23-093897-index-headers.html Edgar Link pending
0001213900-23-093897-index.html Edgar Link pending
0001213900-23-093897.txt Edgar Link pending
0001213900-23-093897-xbrl.zip Edgar Link pending
f10q0923ex31-1_virpax.htm Edgar Link pending
f10q0923ex31-2_virpax.htm Edgar Link pending
f10q0923ex32-1_virpax.htm Edgar Link pending
f10q0923_virpaxpharma.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
f10q0923_virpaxpharma_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vrpx-20230930.xsd Edgar Link pending
vrpx-20230930_cal.xml Edgar Link unprocessable
vrpx-20230930_def.xml Edgar Link unprocessable
vrpx-20230930_pre.xml Edgar Link unprocessable